What is TechsoMed?
TechsoMed is a specialized medical imaging software developer that has carved out a distinct niche in the healthcare technology sector. Its flagship innovation, the BioTrace platform, utilizes sophisticated AI algorithms to provide physicians with real-time visualization of tissue viability during standard ultrasound-guided procedures. This capability is critical for improving outcomes in complex medical fields, including oncology for tumor ablation, cardiology for heart arrhythmia management, and pain management through radiofrequency neurotomy.
By integrating seamlessly with existing commercial ultrasound hardware, TechsoMed effectively lowers the barrier to entry for hospitals and clinics looking to adopt high-precision diagnostic tools. The company's market position is bolstered by its focus on actionable, real-time data, which addresses a significant unmet need for precision in minimally invasive surgical interventions.
How much funding has TechsoMed raised?
TechsoMed has raised a total of $9.6M across 2 funding rounds:
Other Financing Round
$2.6M
Series B
$7M
Other Financing Round (2019): $2.6M with participation from AMIT-Technion, JJDC, NextLeap Ventures, Screen Holdings, and Axil Capital
Series B (2021): $7M led by NextLeap Ventures, Cobro Ventures, Radianx Capital, JLABS companies, Magna Capital Partners, JJDC, Yonjin Venture, and Axil Capital
Key Investors in TechsoMed
JJDC
Johnson & Johnson is a global healthcare company that develops pharmaceuticals and medical technologies. It provides innovative medicines, surgical products, and medical devices used in areas such as oncology, immunology, neuroscience, and cardiovascular care, serving healthcare providers and patients worldwide.
Magna Capital Partners
A forward-looking investment firm that prioritizes collaborative relationships and professional excellence to drive value within the business goals of its portfolio companies.
NextLeap Ventures
A venture capital firm focused on identifying and scaling high-growth technology companies with the potential to disrupt traditional industry standards.
What's next for TechsoMed?
With the recent infusion of capital, TechsoMed is poised to transition from a technology-focused developer to a dominant player in the clinical imaging market. The strategic roadmap likely involves expanding the clinical validation of the BioTrace platform to support broader regulatory approvals and deeper market penetration in the oncology and cardiology sectors.
Furthermore, the company is expected to focus on scaling its operational infrastructure to support global distribution. By maintaining its collaborative approach with strategic healthcare investors, TechsoMed is well-positioned to refine its AI models, ensuring that its software remains at the forefront of diagnostic accuracy. The focus remains on driving long-term value through technological superiority and clinical efficacy, solidifying its role as a critical partner in the future of precision medicine.
